Literature DB >> 17143329

Lentivector-mediated RNAi efficiently suppresses prion protein and prolongs survival of scrapie-infected mice.

Alexander Pfeifer1, Sabina Eigenbrod, Saba Al-Khadra, Andreas Hofmann, Gerda Mitteregger, Markus Moser, Uwe Bertsch, Hans Kretzschmar.   

Abstract

Prion diseases are fatal neurodegenerative diseases characterized by the accumulation of PrP(Sc), the infectious and protease-resistant form of the cellular prion protein (PrP(C)). We generated lentivectors expressing PrP(C)-specific short hairpin RNAs (shRNAs) that efficiently silenced expression of the prion protein gene (Prnp) in primary neuronal cells. Treatment of scrapie-infected neuronal cells with these lentivectors resulted in an efficient and stable suppression of PrP(Sc) accumulation. After intracranial injection, lentiviral shRNA reduced PrP(C) expression in transgenic mice carrying multiple copies of Prnp. To test the therapeutic potential of lentiviral shRNA, we used what we believe to be a novel approach in which the clinical situation was mimicked. We generated chimeric mice derived from lentivector-transduced embryonic stem cells. Depending on the degree of chimerism, these animals carried the lentiviral shRNAs in a certain percentage of brain cells and expressed reduced levels of PrP(C). Importantly, in highly chimeric mice, survival after scrapie infection was significantly extended. Taken together, these data suggest that lentivector-mediated RNA interference could be an approach for the treatment of prion disease.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17143329      PMCID: PMC1679709          DOI: 10.1172/JCI29236

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  47 in total

1.  A quantitative assay for HIV DNA integration in vivo.

Authors:  S L Butler; M S Hansen; F D Bushman
Journal:  Nat Med       Date:  2001-05       Impact factor: 53.440

2.  Expanding small RNA interference.

Authors:  Thomas Tuschl
Journal:  Nat Biotechnol       Date:  2002-05       Impact factor: 54.908

Review 3.  Interventional strategies against prion diseases.

Authors:  A Aguzzi; M Glatzel; F Montrasio; M Prinz; F L Heppner
Journal:  Nat Rev Neurosci       Date:  2001-10       Impact factor: 34.870

4.  A system for stable expression of short interfering RNAs in mammalian cells.

Authors:  Thijn R Brummelkamp; René Bernards; Reuven Agami
Journal:  Science       Date:  2002-03-21       Impact factor: 47.728

5.  Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells.

Authors:  Nan Sook Lee; Taikoh Dohjima; Gerhard Bauer; Haitang Li; Ming-Jie Li; Ali Ehsani; Paul Salvaterra; John Rossi
Journal:  Nat Biotechnol       Date:  2002-05       Impact factor: 54.908

6.  Germline transmission and tissue-specific expression of transgenes delivered by lentiviral vectors.

Authors:  Carlos Lois; Elizabeth J Hong; Shirley Pease; Eric J Brown; David Baltimore
Journal:  Science       Date:  2002-01-10       Impact factor: 47.728

7.  Deletion of the alpha(1,3)galactosyl transferase (GGTA1) gene and the prion protein (PrP) gene in sheep.

Authors:  C Denning; S Burl; A Ainslie; J Bracken; A Dinnyes; J Fletcher; T King; M Ritchie; W A Ritchie; M Rollo; P de Sousa; A Travers; I Wilmut; A J Clark
Journal:  Nat Biotechnol       Date:  2001-06       Impact factor: 54.908

8.  Transgenesis by lentiviral vectors: lack of gene silencing in mammalian embryonic stem cells and preimplantation embryos.

Authors:  Alexander Pfeifer; Masahito Ikawa; Yelena Dayn; Inder M Verma
Journal:  Proc Natl Acad Sci U S A       Date:  2002-02-19       Impact factor: 11.205

Review 9.  Gene therapy: promises and problems.

Authors:  A Pfeifer; I M Verma
Journal:  Annu Rev Genomics Hum Genet       Date:  2001       Impact factor: 8.929

10.  Efficient and specific down-regulation of prion protein expression by RNAi.

Authors:  G Tilly; J Chapuis; D Vilette; H Laude; J L Vilotte
Journal:  Biochem Biophys Res Commun       Date:  2003-06-06       Impact factor: 3.575

View more
  51 in total

Review 1.  Lentiviral vector-mediated gene transfer and RNA silencing technology in neuronal dysfunctions.

Authors:  Jean-Luc Dreyer
Journal:  Mol Biotechnol       Date:  2011-02       Impact factor: 2.695

Review 2.  Antisense makes sense in engineered regenerative medicine.

Authors:  Yongchang Yao; Chunming Wang; Rohan R Varshney; Dong-An Wang
Journal:  Pharm Res       Date:  2008-11-18       Impact factor: 4.200

3.  Inhibition of latent transforming growth factor-beta1 activation by lentivirus-mediated short hairpin RNA targeting the CD36 gene in NR8383 cells.

Authors:  Xin Wang; Ying Chen; Lina Lv; Jie Chen
Journal:  Mol Biol Rep       Date:  2009-06-10       Impact factor: 2.316

4.  Insights into prion biology: integrating a protein misfolding pathway with its cellular environment.

Authors:  Susanne DiSalvo; Tricia R Serio
Journal:  Prion       Date:  2011-04-01       Impact factor: 3.931

5.  Lentivirus-mediated RNA interference targeting E2F-1 inhibits human gastric cancer MGC-803 cell growth in vivo.

Authors:  Xiao Tong Wang; Yu Bo Xie; Qiang Xiao
Journal:  Exp Mol Med       Date:  2011-11-30       Impact factor: 8.718

6.  siRNA Therapeutics for Protein Misfolding Diseases of the Central Nervous System.

Authors:  Mark D Zabel; Luke Mollnow; Heather Bender
Journal:  Methods Mol Biol       Date:  2021

7.  Modifiers of prion protein biogenesis and recycling identified by a highly parallel endocytosis kinetics assay.

Authors:  Boris A Ballmer; Rita Moos; Prisca Liberali; Lucas Pelkmans; Simone Hornemann; Adriano Aguzzi
Journal:  J Biol Chem       Date:  2017-03-24       Impact factor: 5.157

8.  Liposome-siRNA-peptide complexes cross the blood-brain barrier and significantly decrease PrP on neuronal cells and PrP in infected cell cultures.

Authors:  Bruce Pulford; Natalia Reim; Aimee Bell; Jessica Veatch; Genevieve Forster; Heather Bender; Crystal Meyerett; Scott Hafeman; Brady Michel; Theodore Johnson; A Christy Wyckoff; Gino Miele; Christian Julius; Jan Kranich; Alan Schenkel; Steven Dow; Mark D Zabel
Journal:  PLoS One       Date:  2010-06-14       Impact factor: 3.240

9.  RNAi reduces expression and intracellular retention of mutant cartilage oligomeric matrix protein.

Authors:  Karen L Posey; Peiman Liu; Huiqiu R Wang; Alka C Veerisetty; Joseph L Alcorn; Jacqueline T Hecht
Journal:  PLoS One       Date:  2010-04-22       Impact factor: 3.240

10.  Lipopeptide delivery of siRNA to the central nervous system.

Authors:  Mark D Zabel
Journal:  Methods Mol Biol       Date:  2013
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.